Literature DB >> 20802969

[Chagas cardiomyopathy: prognosis in clinical and hemodynamic profile C].

Juliano Cardoso1, Milena Novaes, Marcelo Ochiai, Kelly Regina, Paulo Morgado, Robinson Munhoz, Euler Brancalhão, Marcelo Lima, Antonio Carlos Pereira Barretto.   

Abstract

BACKGROUND: patients with heart failure (HF) who are admitted showing poor perfusion and congestion (clinical-hemodynamic profile C) are the group that evolves with the worst prognosis in decompensated heart failure. However, there is little information in literature on the etiology of cardiopathy influences the outcome of patients in advanced stage.
OBJECTIVE: to assess the outcome of patients admitted with clinical and hemodynamic profile C and verify the role of the etiology in this phase.
METHODS: a cohort study was performed including patients with left ventricle ejection fraction (LVEF) < 45.0%, functional class IV and hospitalization presenting clinical-hemodynamic profile C. The group was divided into patients with chagasic (Ch) and non chagasic (NCh) cardiomyopathy. Statistical analysis used Student t test, Fisher exact test, chi-square and SPSS tests. The significance of p < 0.05 was considered.
RESULTS: one hundred patients, with mean age 57.6 ± 15.1 years and mean LVEF of 23.8 ± 8.5%, were included. Among the patients studied, 33.0% were chagasic and, in comparison with NCh, had lower systolic blood pressure (Ch 89.3 ± 17.1 mmHg versus NCh 98.8 ± 21.7 mmHg, p = 0.03 ) and lowest average age - Ch 52.9 ± 14.5 years versus NCh 59.8 ± 14.9 years, p = 0.03). During follow-up of 25 months, mortality was 66.7% for Ch and 37.3% in NCh (p = 0.019). The Chagas disease etiology was an independent marker of poor prognosis in multivariate analysis with risk ratio of 2.75 (HF 95.0%, from 1.35 to 5.63).
CONCLUSION: in patients with advanced HF, Chagas disease is an important predictor of the worst prognosis.

Entities:  

Mesh:

Year:  2010        PMID: 20802969     DOI: 10.1590/s0066-782x2010005000112

Source DB:  PubMed          Journal:  Arq Bras Cardiol        ISSN: 0066-782X            Impact factor:   2.000


  4 in total

1.  Effect of physical exercise training in patients with Chagas heart disease: study protocol for a randomized controlled trial (PEACH study).

Authors:  Fernanda de Souza Nogueira Sardinha Mendes; Andréa Silvestre Sousa; Fernando Cesar de Castro Cesar Souza; Vivian Liane Mattos Pinto; Paula Simplicio Silva; Roberto Magalhães Saraiva; Sergio Salles Xavier; Henrique Horta Veloso; Marcelo Teixeira Holanda; Andréa Rodrigues Costa; Fernanda Martins Carneiro; Gilberto Marcelo Sperandio Silva; Juliana Pereira Borges; Eduardo Tibirica; Roberta Olmo Pinheiro; Flávio Alves Lara; Alejandro Marcel Hasslocher-Moreno; Pedro Emmanuel Alvarenga Americano Brasil; Mauro Felippe Felix Mediano
Journal:  Trials       Date:  2016-09-02       Impact factor: 2.279

2.  Mortality risk in chronic Chagas cardiomyopathy: a systematic review and meta-analysis.

Authors:  Sindhu Chadalawada; Anis Rassi; Omar Samara; Anthony Monzon; Deepika Gudapati; Lilian Vargas Barahona; Peter Hyson; Stefan Sillau; Luisa Mestroni; Matthew Taylor; Maria da Consolação Vieira Moreira; Kristen DeSanto; Nelson I Agudelo Higuita; Carlos Franco-Paredes; Andrés F Henao-Martínez
Journal:  ESC Heart Fail       Date:  2021-10-30

3.  Short-term add-on therapy with angiotensin receptor blocker for end-stage inotrope-dependent heart failure patients: B-type natriuretic peptide reduction in a randomized clinical trial.

Authors:  Marcelo E Ochiai; Euler C O Brancalhão; Raphael S N Puig; Kelly R N Vieira; Juliano N Cardoso; Múcio Tavares de Oliveira; Antonio C P Barretto
Journal:  Clinics (Sao Paulo)       Date:  2014       Impact factor: 2.365

Review 4.  Increased mortality attributed to Chagas disease: a systematic review and meta-analysis.

Authors:  Zulma M Cucunubá; Omolade Okuwoga; María-Gloria Basáñez; Pierre Nouvellet
Journal:  Parasit Vectors       Date:  2016-01-27       Impact factor: 3.876

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.